Recent advances in neoantigen vaccines for treating non-small cell lung cancer

Area of Science:

• Immunology and Oncology
• Cancer Therapeutics

Background:

• Programmed cell death protein 1 (PD-1) blockade therapy has revolutionized non-small cell lung cancer (NSCLC) treatment.
• Therapy success is linked to high tumor mutation burden and lung cancer cell immunogenicity.
• Resistance to current immunotherapies necessitates novel approaches to enhance active immune responses.

Purpose of the Study:

• To review advances in neoantigen vaccines and neoantigen-based therapies for cancer, specifically NSCLC.
• To discuss the identification of neoantigens in NSCLC patients and relevant mutations.
• To explore strategies for improving NSCLC immunotherapy efficacy beyond immune checkpoint blockade.

Main Methods:

• Review of current literature on neoantigen vaccines in cancer treatment.
• Analysis of preclinical studies and early-phase clinical trials of neoantigen-based NSCLC therapies.
• Examination of methods for neoantigen identification in NSCLC patients.

Main Results:

• Neoantigens are highly immunogenic and specific targets for cancer immunotherapy.
• Neoantigen vaccines and therapies demonstrate potential in preclinical and early clinical settings for NSCLC.
• Recent studies have identified candidate mutations for neoantigen targeting in NSCLC.

Conclusions:

• Neoantigen-targeting approaches are a promising strategy to enhance NSCLC immunotherapy.
• These strategies, alongside immune checkpoint blockade, could overcome resistance and improve treatment efficacy.
• Further research into neoantigen identification and therapeutic application is warranted for NSCLC.